V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10438319 | 10041812 | 1.68 | 50.4 | null | 2020-03-16 | 2020-03-29 | ATEZOLIZUMAB + BEVACIZUMAB | Y | N | ATEZOLIZUMAB + CARBOPLATIN + ETOPOSIDE | 100823772 |
| 10438328 | 10041814 | 1.66 | 63 | Curative (C) | 2019-08-14 | 2019-08-24 | DABRAFENIB | 02 | null | SORAFENIB | 100496099 |
| 10438624 | 10041817 | 1.74 | 60.1 | 03 | 2019-08-31 | 2019-11-19 | null | 02 | N | BORTEZOMIB + CYCLOPHOSPHAMIDE + THALIDOMIDE | 100580316 |
| 10438757 | 10041819 | 1.78 | 63 | Neo-adjuvant (N) | 2019-04-21 | 2019-04-27 | THALIDOMIDE | 02 | N | AML19 TRIAL | 101119060 |
| 10438846 | 10041821 | null | null | 03 | 2017-10-24 | 2019-09-27 | null | 02 | N | TIVOZANIB | 100804620 |
| 10438863 | 10041822 | 1.48 | 121 | Curative (C) | 2019-08-05 | 2019-08-12 | FLUOROURACIL + MITOMYCIN + RT | N | null | TRASTUZUMAB | 100663825 |
| 10438924 | 10041824 | 1.58 | 68.15 | Palliative (P) | 2018-07-06 | 2018-07-06 | Carboplatin + Paclitaxel + Pembrolizumab | 02 | null | FLUDARABINE + MITOXANTRONE | 101309867 |
| 10439142 | 10041829 | null | null | Palliative (P) | null | 2019-11-12 | Irinotecan + Modified De Gramont | 02 | N | CISPLATIN + DOCETAXEL + FLUOROURACIL | 100337421 |
| 10439175 | 10041830 | 0 | 73.4 | null | 2020-01-28 | 2020-02-28 | Bortezomib + Daratumumab | 02 | N | CTD | 100598928 |
| 10439306 | 10041831 | 1.68 | 73 | 03 | 2018-08-25 | 2018-08-25 | AVELUMAB + AXITINIB | Y | null | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB + VINCRISTINE | 101529428 |
| 10439350 | 10041832 | 1.75 | 76.4 | Palliative (P) | 2020-01-06 | 2020-01-27 | Carboplatin + Paclitaxel + Pembrolizumab | 02 | null | CYCLOPHOSPHAMIDE + CYTARABINE + DOXORUBICIN + ETOPOSIDE + IFOSFAMIDE + METHOTREXATE + RITUXIMAB + VINCRISTINE | 101300168 |
| 10439361 | 10041833 | 1.82 | 87.6 | Palliative (P) | 2019-10-20 | 2019-11-19 | Trastuzumab | 02 | N | PRISM TRIAL | 100211794 |
| 10439378 | 10041834 | 1.7 | 82 | Curative (C) | 2017-08-15 | 2017-09-19 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | CISPLATIN + CAPECITABINE + EPIRUBICIN | 101525073 |
| 10439512 | 10041836 | 1.75 | 80.5 | Disease modification (D) | 2017-06-05 | 2017-06-08 | Bortezomib + Panobinostat + Thalidomide | N | N | METHOTREXATE | 100856794 |
| 10439696 | 10041838 | 1.65 | null | Neo-adjuvant (N) | null | 2018-12-04 | Myeloma XV Trial | N | N | BOSUTINIB | 100148034 |
| 10439777 | 10041839 | 1.6 | 0 | null | 2019-04-12 | 2019-04-25 | TRANSPLANT ATG + BUSULFAN + FLUDARABINE | 02 | null | FULVESTRANT + PALBOCICLIB | 101179068 |
| 10439817 | 10041841 | 1.73 | 78 | Palliative (P) | 2020-02-05 | 2020-02-09 | Obinutuzumab + Venetoclax | 02 | N | BORTEZOMIB + MELPHALAN | 100630419 |
| 10439892 | 10041842 | 1.63 | 63.3 | Neo-adjuvant (N) | 2018-01-21 | 2018-02-14 | Carboplatin + Liposomal Doxorubicin | 02 | N | CYCLOPHOSPHAMIDE + DOCETAXEL + TRASTUZUMAB | 100767146 |
| 10439950 | 10041844 | 1.71 | 85 | Neo-adjuvant (N) | 2016-06-19 | 2016-07-18 | null | null | null | ATEZOLIZUMAB | 101827760 |
| 10439983 | 10041845 | null | null | Curative (C) | 2017-07-04 | 2017-07-10 | Tretinoin | 01 | N | CISPLATIN + ETOPOSIDE | 101010495 |
| 10440122 | 10041848 | 1.81 | 60.3 | Curative (C) | null | 2018-12-28 | CVP | null | null | BLEOMYCIN + DACARBAZINE + DOXORUBICIN + VINBLASTINE | 101570236 |
| 10440145 | 10041849 | 1.81 | 55.3 | Adjuvant (A) | 2020-01-25 | 2020-02-11 | FEC + DOCETAXEL + TRASTUZUMAB | 02 | N | VINORELBINE | 101803315 |
| 10440151 | 10041850 | 1.75 | 74.3 | null | 2018-12-05 | 2018-12-09 | ETOPOSIDE | 02 | null | SORAFENIB | 101402451 |
| 10440163 | 10041851 | 1.75 | 66.8 | 03 | 2019-05-15 | 2019-05-21 | null | null | null | CHLORAMBUCIL + PROCARBAZINE + VINBLASTINE | 100235272 |
| 10440226 | 10041852 | 1.71 | 83.4 | Palliative (P) | 2020-01-13 | 2020-01-31 | FCR | null | null | SPIRE TRIAL | 100812512 |
| 10440345 | 10041853 | 1.71 | 86.7 | Curative (C) | 2018-09-25 | 2018-09-28 | Bortezomib + Daratumumab | 2 | N | CARBOPLATIN + FLUOROURACIL | 101581018 |
| 10440368 | 10041854 | 1.58 | null | null | 2019-01-18 | 2019-01-18 | null | 02 | null | DABRAFENIB | 101713287 |
| 10440406 | 10041855 | 1.57 | 76 | Palliative (P) | 2017-04-26 | 2017-04-27 | AML 18 TRIAL | 02 | N | CARBOPLATIN + LIPOSOMAL DOXORUBICIN | 100972117 |
| 10440452 | 10041856 | 1.77 | 77 | null | 2019-12-18 | 2019-12-19 | Capecitabine (14 day) + Irinotecan | 02 | N | AZACITIDINE + VENETOCLAX | 100945468 |
| 10440586 | 10041857 | 1.85 | 85 | null | 2020-04-15 | 2020-04-19 | Bortezomib + Cyclophos + Dex | 02 | N | MYELOMA XI TRIAL | 100119563 |
| 10440602 | 10041858 | 1.49 | 116.4 | Curative (C) | 2022-01-02 | 2022-01-02 | ECF | 2 | null | BEXAROTENE | 101184031 |
| 10440649 | 10041859 | 1.61 | 122 | Palliative (P) | 2020-04-07 | 2020-04-07 | Sorafenib | 02 | N | GEFITINIB | 100497212 |
| 10440797 | 10041860 | 1.57 | 83.6 | Palliative (P) | null | 2019-07-08 | DACARBAZINE + DOXORUBICIN + VINBLASTINE | N | N | OXALIPLATIN + MDG | 100552559 |
| 10440834 | 10041861 | 1.7 | 74 | 03 | null | 2019-04-30 | OXALIPLATIN + MDG + PANITUMUMAB | N | null | ENRICH TRIAL | 101778124 |
| 10440846 | 10041862 | null | null | Neo-adjuvant (N) | 2017-05-08 | 2017-05-23 | Tivozanib | 02 | Y | METHOTREXATE | 100952664 |
| 10440848 | 10041863 | 1.8 | 59.4 | Palliative (P) | 2019-05-05 | 2019-05-16 | R CODOX M | N | N | AML17 TRIAL | 101687451 |
| 10440897 | 10041864 | 1.46 | 60 | Curative (C) | 2019-03-05 | 2019-03-05 | Obinutuzumab +CVP | 02 | null | CARBOPLATIN + EPIRUBICIN | 101477320 |
| 10440901 | 10041865 | 1.68 | 80.9 | 03 | 2020-03-23 | 2020-10-28 | R CODOX-M/ R IVAC | N | null | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN | 100735669 |
| 10440928 | 10041867 | 1.55 | 95 | Disease modification (D) | 2020-02-14 | 2020-03-02 | Bortezomib + Cyclophos + Dex | 02 | null | CTD | 101293525 |
| 10440931 | 10041868 | 1.73 | 73 | null | null | 2021-11-14 | Letrozole + Palbociclib | 02 | null | AFATINIB | 101588954 |
| 10441223 | 10041873 | 1.58 | 70.6 | Curative (C) | 2018-11-12 | 2018-11-12 | IDELALISIB + RITUXIMAB | 02 | null | MYELOMA XI TRIAL | 101682008 |
| 10441321 | 10041874 | 1.75 | 65 | Adjuvant (A) | 2018-08-29 | 2018-08-29 | CAPECITABINE + CETUXIMAB | 2 | N | AFATINIB | 100975333 |
| 10441327 | 10041875 | 0 | null | Palliative (P) | 2021-06-16 | 2021-06-16 | CAPECITABINE + CARBOPLATIN | 02 | N | IXAZOMIB | 100323401 |
| 10441407 | 10041876 | 1.64 | 54.8 | 03 | 2018-12-24 | 2019-01-06 | AZACITIDINE + VENETOCLAX | 02 | N | CHLORAMBUCIL + PROCARBAZINE + VINBLASTINE | 100384035 |
| 10441605 | 10041879 | 0 | 0 | Palliative (P) | 2018-05-24 | 2018-05-29 | null | 02 | N | OBINUTUZUMAB + VENETOCLAX | 100961103 |
| 10441650 | 10041880 | 1.81 | 72.6 | Palliative (P) | 2018-09-15 | 2018-09-27 | TRASTUZUMAB EMTANSINE | 02 | N | LIPOSOMAL DAUNORUBICIN + LIPOSOMAL CYTARABINE (VYXEOS) | 100413108 |
| 10441740 | 10041881 | 1.69 | 72 | Disease modification (D) | 2018-11-13 | 2018-11-21 | Obinutuzumab +CHOP | 02 | null | MELPHALAN | 100490571 |
| 10441798 | 10041882 | 1.6 | 66.8 | 03 | 2020-05-18 | 2020-06-05 | Binimetinib + Encorafenib | 02 | N | OCTREOTIDE | 100540903 |
| 10442009 | 10041883 | 0 | 69 | 03 | 2016-02-13 | 2019-06-18 | ABVD | 2 | null | CYTARABINE + DAUNORUBICIN | 100067737 |
| 10442117 | 10041885 | 1.77 | null | null | 2021-04-07 | 2021-04-22 | AML 18 TRIAL | 02 | null | CHOP | 101357773 |